ARS Pharmaceuticals, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

ARS Pharmaceuticals, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $84.28 million for the year ending 2025.

  • ARS Pharmaceuticals, Inc. showed a decrease of -5.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), ARS Pharmaceuticals, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,430.7%.
  • Historical annual values: Fiscal year 2025: $84.28 million | Fiscal year 2024: $89.15 million | Fiscal year 2023: $30.0 thousand | Fiscal year 2022: $1.32 million | Fiscal year 2021: $5.51 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: